Shots:
- OS Therapies joined hands with EVERSANA to commercialize OST-HER2 in the US for the treatment of pediatric lung metastatic osteosarcoma
- This partnership leverages EVERSANA’s integrated commercialization platform, including market access, medical affairs, field deployment, patient services, and stakeholder engagement enabling OS Therapies to bring OST-HER2 to market rapidly and cost-effectively
- OS Therapies recently secured U.S. Patent #12,239,738, providing commercial manufacturing exclusivity for OST-HER2 and its broader Listeria-based immunotx. platform through 2040. The company is targeting a rolling BLA submission in the 3Q’25, with potential FDA approval in H2’25
Ref: Ostherapies | Image: Ostherapies | Press Release
Related News:- OS Therapies Reports Clinical Data of OST-HER2 for the Treatment of Unresected Osteosarcoma in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
